Literature DB >> 25366691

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.

Gerald S Falchook1, Nelson G Ordóñez2, Christel C Bastida2, Philip J Stephens3, Vincent A Miller3, Lindsay Gaido2, Tiffiny Jackson2, Daniel D Karp2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25366691     DOI: 10.1200/JCO.2013.50.5016

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  28 in total

1.  Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.

Authors:  Dennis Plenker; Maximilian Riedel; Johannes Brägelmann; Marcel A Dammert; Rakhee Chauhan; Phillip P Knowles; Carina Lorenz; Marina Keul; Mike Bührmann; Oliver Pagel; Verena Tischler; Andreas H Scheel; Daniel Schütte; Yanrui Song; Justina Stark; Florian Mrugalla; Yannic Alber; André Richters; Julian Engel; Frauke Leenders; Johannes M Heuckmann; Jürgen Wolf; Joachim Diebold; Georg Pall; Martin Peifer; Maarten Aerts; Kris Gevaert; René P Zahedi; Reinhard Buettner; Kevan M Shokat; Neil Q McDonald; Stefan M Kast; Oliver Gautschi; Roman K Thomas; Martin L Sos
Journal:  Sci Transl Med       Date:  2017-06-14       Impact factor: 17.956

Review 2.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

3.  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Authors:  Oliver Gautschi; Julie Milia; Thomas Filleron; Juergen Wolf; David P Carbone; Dwight Owen; Ross Camidge; Vignhesh Narayanan; Robert C Doebele; Benjamin Besse; Jordi Remon-Masip; Pasi A Janne; Mark M Awad; Nir Peled; Chul-Cho Byoung; Daniel D Karp; Michael Van Den Heuvel; Heather A Wakelee; Joel W Neal; Tony S K Mok; James C H Yang; Sai-Hong Ignatius Ou; Georg Pall; Patrizia Froesch; Gérard Zalcman; David R Gandara; Jonathan W Riess; Vamsidhar Velcheti; Kristin Zeidler; Joachim Diebold; Martin Früh; Sebastian Michels; Isabelle Monnet; Sanjay Popat; Rafael Rosell; Niki Karachaliou; Sacha I Rothschild; Jin-Yuan Shih; Arne Warth; Thomas Muley; Florian Cabillic; Julien Mazières; Alexander Drilon
Journal:  J Clin Oncol       Date:  2017-03-13       Impact factor: 44.544

Review 4.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

5.  Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.

Authors:  Zhenya Tang; Jianjun Zhang; Xinyan Lu; Wei Wang; Hui Chen; Melissa K Robinson; Joanne Cheng; Guilin Tang; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2017-09-15       Impact factor: 7.842

6.  The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Authors:  Bob T Li; Tristan A Barnes; David L Chan; Jarushka Naidoo; Adrian Lee; Mustafa Khasraw; Gavin M Marx; Mark G Kris; Stephen J Clarke; Alexander Drilon; Charles M Rudin; Nick Pavlakis
Journal:  Lung Cancer       Date:  2016-10-17       Impact factor: 5.705

7.  Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.

Authors:  Casey J N Mathison; Donatella Chianelli; Paul V Rucker; John Nelson; Jason Roland; Zhihong Huang; Yang Yang; Jiqing Jiang; Yun Feng Xie; Robert Epple; Badry Bursulaya; Christian Lee; Mu-Yun Gao; Jennifer Shaffer; Sergio Briones; Yelena Sarkisova; Anna Galkin; Lintong Li; Nanxin Li; Chun Li; Su Hua; Shailaja Kasibhatla; Jacqueline Kinyamu-Akunda; Rie Kikkawa; Valentina Molteni; John E Tellew
Journal:  ACS Med Chem Lett       Date:  2020-02-12       Impact factor: 4.345

8.  A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.

Authors:  Konrad Klinghammer; James Keller; Jonathan George; Jens Hoffmann; Edward L Chan; Michael J Hayman
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

Review 9.  Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.

Authors:  Anna F Farago; Christopher G Azzoli
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 10.  Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.

Authors:  Motonobu Saito; Hiroyuki Suzuki; Koji Kono; Seiichi Takenoshita; Takashi Kohno
Journal:  Surg Today       Date:  2017-03-09       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.